| 0.8901 -0.01 (-1.1%) | 10-21 12:49 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 1.21  |
1-year : | 1.35 |
| Resists | First : | 1.04 |
Second : | 1.15 |
| Pivot price | 0.96 |
|||
| Supports | First : | 0.85 | Second : | 0.7 |
| MAs | MA(5) : | 0.9 |
MA(20) : | 0.97 |
| MA(100) : | 1.6 |
MA(250) : | 2.66 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.2 |
| %K %D | K(14,3) : | 18.1 |
D(3) : | 19.2 |
| RSI | RSI(14): 37.3 |
|||
| 52-week | High : | 4.86 | Low : | 0.85 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ PLUR ] has closed above bottom band by 29.9%. Bollinger Bands are 55.9% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 15 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 0.95 - 0.96 | 0.96 - 0.96 |
| Low: | 0.88 - 0.88 | 0.88 - 0.89 |
| Close: | 0.89 - 0.9 | 0.9 - 0.91 |
Pluri Inc., a biotechnology company established in 2001 and headquartered in Haifa, Israel, specializes in developing innovative placenta-derived cell therapies. Its core mission is to tackle a range of inflammatory conditions, muscle injuries, and hematological disorders. The company's therapeutic pipeline centers on placental expanded (PLX) cell technology. A key candidate, PLX-PAD, is in advanced clinical development, with ongoing Phase III trials for muscle recovery after hip fracture surgery, Phase II studies for acute respiratory distress syndrome associated with COVID-19, and Phase I/II trials for steroid-refractory Graft-versus-Host Disease. Additionally, Pluri is advancing PLX-R18, a treatment designed to aid in incomplete hematopoietic recovery following hematopoietic cell transplantation and to address acute radiation syndrome. The company rebranded to Pluri Inc. in July 2022, having previously operated as Pluristem Therapeutics Inc.
Wed, 21 Oct 2026
A chairman agreed to take over Pluri's loan from the EU's investment bank. The debt remains. - Stock Titan
Tue, 20 Oct 2026
Pluri Raises $1.25 Million in Private Placement to Largest Holder, Issues Matching Warrant - TradingView
Fri, 16 Oct 2026
Pluri Inc. SEC Filing (Oct 16, 2026) - Stock Titan
Sun, 04 Oct 2026
PLUR Q2 2026 Earnings: Wider-Than-Expected Loss Weighs on Shares - Forward Guidance Trends - dars.gov.et
Mon, 28 Sep 2026
PLUR: Pluri Inc Latest Stock Price, Analysis, News and Trading Ideas - Stocktwits
Thu, 10 Sep 2026
Pluri Inc. FY 2026: Revenue $1.02M, EPS $(2.44) — 10-K Summary - TradingView
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 13 (M) |
| Held by Insiders | 6.12e+006 (%) |
| Held by Institutions | 42.5 (%) |
| Shares Short | 26 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -2.443e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -1 % |
| Return on Assets (ttm) | 655.5 % |
| Return on Equity (ttm) | -49.1 % |
| Qtrly Rev. Growth | 1.02e+006 % |
| Gross Profit (p.s.) | -22.9 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 656522 |
| Qtrly Earnings Growth | -2.5 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -20 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | -0.3 |
| Dividend | 0 |
| Forward Dividend | 19310 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|